This Article  • Full text  • PDF  • Original Article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Journalology/ Peer Review/ Authorship  • Medical Practice  • Conflict of Interest  • Genetics  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: I would like to sincerely apologize to the editors and readers of JAMA for failing to note in the financial disclosure of my Commentary¹ that I am listed as a coinventor in a US Government Provisional Patent Application (Published Patent Application No. 20080113355) filed in 2006, one portion of which relates to a screening method for detecting expanded CGG repeats. The original funding/support statement is correct as given, as is the financial disclosure statement by my coauthor (R. J. Hagerman). However, I neglected to report the filed application, an omission that I now realize was an error in judgment on my part. I sincerely regret any lack of transparency that my failure to report this information may have created.

I also wish to disclose a collaborative arrangement with Asuragen relevant to fragile X screening; the collaboration does not involve any financial compensation, and I do not have . . . [Full Text of this Article]

Paul J. Hagerman, MD, PhD
pjhagerman@ucdavis.edu
Department of Biochemistry and Molecular Medicine
School of Medicine
University of California, Davis

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Testing for Fragile X Gene Mutations Throughout the Life Span
Randi J. Hagerman and Paul J. Hagerman
JAMA. 2008;300(20):2419-2421.
EXTRACT | FULL TEXT